Similarly, dependence on aurora kinases (AURK) arising from RB1 loss [59] (coupled with AURKA mediated acquired resistance to EGFR TKIs in RB1 proficient clones [60]) may open doors to combination therapies with aurora kinase inhibitors, e.g., a phase 1/1b clinical trial of AURKA inhibitor alisertib with osimertinib in metastatic EGFR-mutant lung cancer (NCT04085315). Here, EGFR is linked to lung cancer.